Inverness Medical Innovations invests $92.5 million in Abbott rapid diagnostic lines
This article was originally published in Clinica
Executive Summary
Inverness Medical Innovations has acquired a package of rapid diagnostic product lines from Abbott Laboratories for $92.5m in cash and stock. The products, 90% of which test for pregnancy and streptococcal infection, are currently worth around $50m in annual revenues to IMI, CEO Ron Zwanziger said.
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.